Member Info for chrishutch

tiny amount of shares sold to be fair.

Smoke and mirrors perhaps.

Trying to make my trades more accountable. No not circulated, well other than for improvement from friends and on here. They are not so much a buy recommendation as a way of me improving my abilities. I use social sites to gauge sentiment - if people who regularly make good calls are interested then I note that down. (not my place to name, names)

My stop was placed below the charting furniture, ideally, I would like it tighter but allowing for the spread. I do not want to be stopped out so it is a mental stop. The trade numbers were more a guideline on my part. I will scale in assuming we move up. Thank you for the response.

https://drive.google.com/file/d/14kD_mDtD0vsTisLd3mH8k3MLpZuanSKI/view?usp=sharing

Happy for others to help out if I have missed something or got something wrong.

Also good to see corrections made to https://total-market-solutions.com/2019/03/14/jangadas-road-to-recovery/

Highlights a lot of the potential here and remember there are not many shares available with 69.5% not in public hands. That is a plus considering there is only 235 mill in issue.

After seeing Andrew Monks tweet. Still trying to get my head around what the company is about but looked interesting.

Cliveas or in ROCK's case the other way round, quiet during the storm and now about to LOUD haha.

TIDM: STX

RNS Number : 9328S

Shield Therapeutics PLC

14 March 2019

Shield Therapeutics plc

("Shield" or the "Group")

European Patent Office reaches positive decision on Feraccru(R)'s process patent

London, UK, 14 March 2019: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru(R), announces that, further to Shield's announcement on 24 January 2019 and in relation to the Group's patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone", the Opposition Division of the European Patent Office (EPO) has today decided in favour of Shield.

The decision by the EPO, which was reached having taken into account Shield's first and preferred minor amendment, follows a hearing in relation to the opposition that had been filed against the patent by a third party. This means that the patent as amended and the invention to which it relates meet the requirements of the European Patent Convention and they will continue to provide protection to Feraccru(R) through to 2032.

Customary rights of appeal apply to the third-party opposition and Shield will continue to proactively and robustly defend its intellectual property.

- Ends -

Took a punt here.

I thought it was good, seems strange to see a couple of sellers when the price is clearly moving in the right direction, company moving forward and a very large amount of shares not available.

It screams buy to me, who doesn't like a chart that starts in the bottom left corner and finishes in the top right.

I tried to add more this morning but they moved the price up! Still, my top remains waiting should the price move.

Seems to be just us.. Not a crowded one this, until it is..

This is a firm favorite of mine and I was content with my holding but the more I look at it the more I am tempted to add some.

judging from the amount of HZM in my twitter feed we may well see a chunk of buying.

Just reading through RNS looks positive.

:-)

I took the opportunity to increase my punt as the drop seemed to be more MMs than actual trades. Fingers crossed it pays off, down at this level it feels like a no brainer. Time will tell.

Huge trades - happy to see buyer(s) taking huge trades.

When they let it go, what's the betting they pay it up!

haha thought I would stick ma head in and see what is happening.

I am happy enough to have a small stake here. Will add to it when price moves up.

This churn will soon be done and the price will move up.

:-)